Skip to main content
OpenTrials
Completed

NCT Number: NCT05605223

Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France

The number of acute encephalitides diagnosed each year is gradually increasing, reaching approximately 5 to 10/100,000 per year; more than 50% of etiologies currently remain unknown. The majority of them are acute encephalitis of infectious origin, but it is estimated that 20% of encephalitis in northern Europe is related to an autoimmune mechanism with the majority of encephalitis with anti-NMDA Ac discovered recently in 2007. The study of a large American encephalitis cohort showed a death rate of 3% to 7% in cases of autoimmune encephalitis. Furthermore, delay in the initiation of effective treatment (tumor removal or immunotherapy) beyond 4 weeks is associated with a poor prognosis at 1 year.

It is therefore necessary to better understand the signs of autoimmune encephalitis in order to recognize the disease quickly and to start a treatment quickly; in order to improve the management and the prognosis of these children.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Autoimmune Encephalitis Autoimmune Diseases Autoimmune Diseases of the Nervous System Brain Diseases Central Nervous System Diseases Encephalitis Immune System Diseases Nervous System Diseases Neuroinflammatory Diseases

Age range

1 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, 67091, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 0 and 17 years at diagnosis
  • Patient diagnosed between 01/01/2006 and 31/12/2018 with autoimmune encephalitis in one of the participating university hospitals (Besançon, Nancy, Strasbourg, Reims and Dijon)
  • Presence of clinical criteria of clinical and/or radiographic encephalitis
  • Presence of one or more antibodies in the blood or CSF
  • Parental authority holders and their child of childbearing age having given their consent for the use of the child's data for this research

Exclusion criteria

  • Refusal to participate in the study
  • Absence of consultation at any of the study centers
  • Absence of clinical and/or radiographic criteria for encephalitis.
  • Absence of antibodies found in blood or CSF

Treatment and study plan

Primary outcomes

  1. Retrospective description of autoimmune encephalitis in children

    Time frame: Files analysed retrospectively from January 01, 2006 to December 31, 2018 will be examined

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France Between 2006 and 2018

Acronym: Encephalitis

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Nov 4, 2022
Registry last updated
Dec 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.